A Phase 3b clinical trial involving tirzepatide is recruiting participants as of August 6, 2026. The study, registered as NCT06937086, is titled "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight."
The trial is designed for adults who have moderately to severely active ulcerative colitis along with obesity or overweight. According to the registration, the study evaluates mirikizumab administered at the same time as tirzepatide in this patient population.
The trial is listed as Phase 3b and its current status is recruiting. No results have been posted for this study at this time. The registration does not include efficacy or safety outcomes.
This brief reports only the status and design details listed in the trial registration. Readers should consult the official listing at ClinicalTrials.gov for further details on eligibility, study design, and updates as the trial progresses.
For more background on tirzepatide, readers can refer to the compound overview.